Merus NV at Cowen Health Care Conference Transcript
Good afternoon. We are going to continue with our morning session. The next presenter is Ton Logtenberg, Founder and CEO of Merus.
Thank you and thank you very much and thank you for joining me today. Merus is a company that is headquartered in Utrecht, the Netherlands, with a strong presence here at the East Coast in Boston. And we are a company that from the inception has focused on bispecific antibodies. So I will talk about bispecific antibodies and their applications in oncology.
So at a very high level, first the hallmarks of what Merus is today. So we have four clinical stage bispecific antibodies in oncology, three in the clinic and the fourth one, the IND was cleared earlier this year and will be moving into the clinic shortly.
We have for this year projected multiple clinical readouts in the second half of 2019, so I will talk about that as well. We have a very sophisticated platform based on the full-length IgG format. We believe that that is
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |